tirzepatide by lilly launches lower-price weight loss drug without injector pen Lilly escalates compounding challenge after

Inertia and Challenges in Obesity Management In the last decade, several studies have shown that many clinicians perceive obesity as a social and behavioral issue brought on by poor lifestyle choices [7-9], and most reported feeling unprepared for their medical training when it comes to treating patients with overweight, with some believing that treating obesity is futile [8,9]

Hepatology 64 (6), 13651377

For most patients starting GLP-1 treatment for weight management, semaglutide (either Wegovy or compounded) is a common first choice because it has the longest track record, the most clinical data, and the widest availability

But that's eating nothing

When methylation slows, it can contribute to: Because the methylation cycle affects DNA repair, inflammation, and energy metabolism, understanding your MTHFR status can be a powerful step toward personalized prevention and wellness

Fink, T